导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.53% | 1598/4773 |
| 近一周 | -3.06% | 3605/5462 |
| 近一月 | -9.71% | 4830/5421 |
| 近一季 | -17.93% | 4625/5209 |
| 近半年 | -0.44% | 1302/4920 |
| 近一年 | 7.08% | 1359/4366 |
| 近两年 | 110.74% | 470/2954 |
| 近三年 | 68.56% | 325/2253 |
| 成立以来 | 82.54% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.74% 1934/4961 |
35.03% 930/5312 |
- - |
- - |
| 2025 | 48.87% 507/4813 |
-1.55% 2690/3635 |
3.34% 1044/4076 |
47.63% 443/4524 |
-0.88% 2695/4813 |
| 2024 | 15.64% 903/3463 |
-3.50% 1511/2808 |
-5.83% 1804/3014 |
27.71% 210/3129 |
-0.37% 1396/3463 |
| 2023 | -17.15% 1716/2656 |
2.11% 1447/2280 |
-6.68% 1689/2385 |
-8.90% 1745/2515 |
-4.56% 1095/2655 |
| 2022 | -26.78% 1431/2207 |
-18.40% 1331/1919 |
5.52% 883/2016 |
-17.03% 1542/2113 |
2.49% 918/2208 |
| 2021 | 13.86% 350/1822 |
-5.85% 961/1255 |
25.30% 90/1330 |
-5.74% 854/1466 |
2.40% 602/1822 |
| 2020 | - - |
- - |
- - |
6.32% 855/1164 |
14.64% 259/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 平安创业板ETF联接A VS. 长安沪深300非周期A(740101) |